Navigation Links
CuraGen Reports Third Quarter 2008 Financial Results

- Provides financial guidance through second quarter of 2009 -

- Announces partnership intentions around CR011-vcMMAE -

- Conference call to be held today at 11:00 am ET -

BRANFORD, Conn., Nov. 3 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), today reported its financial results for the third quarter of 2008.

During the three month period ended September 30, 2008, CuraGen utilized $3.6 million of cash for operations and ended the quarter with $91.4 million of cash and investments. CuraGen expects to utilize an average of $3 to $4 million of cash per quarter through June 2009. The company expects to end the fourth quarter of 2008 with approximately $87 to $89 million in cash and investments, and end the second quarter of 2009 with approximately $79 to $81 million in cash and investments. CuraGen is also pursuing partnership opportunities around CR011-vcMMAE.

"Since the beginning of 2007, we have systematically strengthened our net cash position by $84 million and reduced our cash burn by 73%. We have sold clinical programs and non-core assets generating $129 million, repurchased debt of $91 million at a discount of $17 million and reduced the operating burn from $13.3 million in the first quarter of 2007 to $3.6 million in the third quarter of 2008. We are now in a position to take advantage of our prudent actions in what has become a financially-distressed environment," commented Dr. Timothy M. Shannon, President and Chief Executive Officer.

For the quarter ended September 30, 2008, CuraGen reported a net loss of $4.0 million, or $0.07 per share, compared to a loss of $9.9 million, or $0.18 per share, for the same period in 2007. For the nine months ended September 30, 2008, CuraGen reported net income of $28.5 million, or $0.50 per share, as compared to net income of $28.0 million, or $0.50 per share, for the same period in 2007. Net income for the nine months ended September 30, 2008 and 2007 was primarily due to a gain of the sale of belinostat and a gain on the extinguishment of debt in the second quarter of 2008, and the sale of 454 Life Sciences Corporation in the second quarter of 2007.

"We are encouraged by the Phase II results and activity of CR011-vcMMAE in patients with metastatic melanoma that we announced concurrently today, and we will be engaging in discussions with potential partners as we develop plans for the advanced stages of development. The goal of a partnership will be to support the financial, development and commercial resources that will be required in advanced development, improving the risk profile to CuraGen shareholders while maintaining upside potential," stated Dr. Shannon. "We are also actively evaluating strategic opportunities that can accelerate an increase in shareholder value."

Conference Call Details and Dial-in Information

Date: Monday, November 3, 2008

Time: 11:00 a.m. EDT

Dial-in: 877-272-5391 (domestic)

706-758-4315 (international)

Passcode: 71190212

Webcast: Access available at

A replay of the conference call will be available starting at 2:00 p.m. Eastern time on Monday, November 3, 2008 through Wednesday, December 3, 2008 by dialing 800-642-1687 (domestic) or 706-645-9291 (international). The passcode for the replay is 71190212. An archive of the webcast will be available for 30 days at

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a clinical-stage biopharmaceutical company developing promising approaches for the treatment of cancer. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit

Forward-Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to the CuraGen's pursuit of partnership opportunities and discussion with potential partners, revenue, expenses, depreciation, amortization, asset impairment charges, losses, income, and future cash utilization and cash and investment positions, the timing and expected results of its clinical programs, and the development and marketability of planned drugs, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, including the risk that CuraGen's pursuit of partnership opportunities will not proceed as planned or that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, as well as risk associated with the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's ability to comply with Nasdaq listing requirements, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to under the section "Risk Factors" in CuraGen's Quarterly Report on Form 10-Q for the quarter ended June 30, 2008, filed with the Securities and Exchange Commission as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, CuraGen's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



Sean Cassidy

Vice President and Chief Financial Officer

(203) 871-4400



(in thousands, except per share data)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

(unaudited) (unaudited)

Collaboration revenue $- $22 $1,174 $66

Operating expenses:

Research and development 3,453 8,074 12,459 30,480

General and administrative 1,076 2,568 4,235 9,631

Restructuring and other charges - 1,058 - 8,537

Total operating expenses 4,529 11,700 16,694 48,648

Gain on sale of intangible asset - - 36,397 -

(Loss) income from operations (4,529) (11,678) 20,877 (48,582)

Interest income 741 1,861 2,471 4,060

Interest expense (226) (1,273) (1,474) (4,172)

Gain on extinguishment of debt - 169 6,991 169

Gain on sale of long-term marketable

securities - 973 - 973

(Loss) income from continuing

operations before income taxes (4,014) (9,948) 28,865 (47,552)

Income tax benefit (provision) 32 50 (362) 160

(Loss) income from continuing

operations (3,982) (9,898) 28,503 (47,392)

Discontinued operations:

Loss from discontinued operations - - - (2,991)

Gain on sale of subsidiary - - - 78,352

Income from discontinued operations - - - 75,361

Net (loss) income ($3,982) ($9,898) $28,503 $27,969

Basic (loss) income per share from

continuing operations ($0.07) ($0.18) $0.50 ($0.85)

Basic income per share from

discontinued operations - - - 1.35

Basic net (loss) income per share ($0.07) ($0.18) $0.50 $0.50

Weighted average number of shares

used in computing:

Basic net (loss) income per share 56,822 55,965 56,693 55,699


September 30, December 31,

2008 2007


Cash and investments $91,428 $100,444

Restricted cash - 14,533

Total cash and investments and restricted cash $91,428 $114,977

Working capital $86,982 $107,844

Total assets $92,585 $119,282

4% Convertible subordinated notes due 2011 $18,967 $69,890

Total long-term liabilities $18,967 $70,975

Accumulated deficit $459,071 $487,574

Stockholders' equity $68,445 $38,465

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CuraGen Repurchases $50.9 Million of 2011 Convertible Debt for $43.2 Million
2. CuraGen Sells Ownership of Belinostat to TopoTarget A/S
3. CuraGen to Present at the BIO CEO & Investor Conference
4. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
5. CuraGen Corporation Receives Notification from NASDAQ
6. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
7. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
8. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
9. CuraGen Appoints Clinical Oncologist as VP of Medical Development
10. CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
11. BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Post Your Comments:
(Date:10/10/2017)... ... October 10, 2017 , ... ... business process optimization firm for the life sciences and healthcare industries, announces a ... in San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting in North ... in Harvard University’s Departments of Physics and Astronomy, has been selected for membership in ... winning team for the 2015 Breakthrough Prize in Fundamental physics for the discovery of ...
(Date:10/9/2017)... Antonio, Texas (PRWEB) , ... ... ... new study published on October 5, 2017, in the medical journal, Epilepsia, ... equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic seizures ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by Solution ... Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022", ... 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at a ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):